Takeaways from this week in optometry: August 3-August 7

From treating myopic complications to preventing them, eye care providers have ample opportunity to close a collaborative care gap.

The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 pm ET and was open to public.

The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.

Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.

The approval followed complete response letters tied to inspection and manufacturing issues.

What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.

This week’s top stories include pipeline updates in dry eye, retinitis pigmentosa, contact lens hygiene, and more.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.